gila

The same medicine. Two very different years.

A weekly GLP-1 starts. From there the year splits: unsupervised escalation, or Gila’s physician-led titration, monitoring, nutrition, and stop plan. Fifteen minutes through both.

See the year Skip to ~12 months

On-treatment weight loss · trial averages

Semaglutide · STEP-1 trial~15% by week 68 (~16 months)
Tirzepatide · SURMOUNT-1 trial~20% by week 72 (~17 months)

15-minute walkthrough

Patient starts GLP-1 treatment

12 minThe fork
24 minWithout Gila — where the year usually breaks
34 minWith Gila — what changes at each beat
43 minIndia eligibility & labs
52 minReferral ask

Path AWithout Gila · unsupervised

Path BWith Gila · physician-led

The year, beat by beat

Week 1–4

Early weight-loss % · first ~6 months · trial averages

Semaglutide · STEP-1 trial~15% by week 68 (~16 months)
Tirzepatide · SURMOUNT-1 trial~20% by week 72 (~17 months)

Without Gila

Dose without a system

GI side effects hit hard during escalation. Without pacing guidance, patients quit early or change doses alone — and unmanaged early stops still reflect on the referring pathway.

With Gila

Physician-supervised titration

Gila runs planned dose steps, symptom guidance, and a clinician to call when side effects spike.

Indian RWE — GI-driven discontinuationNamed

Ongoing

Kilograms lost · 100 kg start · trial end-points

Starting weight 100 kg — mean loss at peak follow-up in curated anchors

Without Gila

Appetite drops — protein often with it

Unmanaged intake risks lean-mass loss. Appetite suppression is not “all fat.”

With Gila

Nutrition to protect lean mass

Gila builds protein targets and resistance-training guidance into the plan.

Muscle / lean-mass systematic reviewNamed

Baseline → follow-up

Peak average weight loss by programme

STEP-1 · week 68Curated
SURMOUNT-1 · week 72Curated

Without Gila

No one watching the labs

No scheduled bloodwork or dose adjustment tied to tolerance and comorbidity progress.

With Gila

Monitoring is part of the plan

Gila schedules check-ins and labs so dose and metabolic progress are tracked — not assumed.

STEP-1 trialNamed
SURMOUNT-1 trialNamed

Month 3–12

Real-world discontinuation

By week 12 (~3 months)

2/10

By week 26 (~6 months)

2/10

By week 52 (~12 months)

4/10

Without Gila

Where most people quit

Stop rates climb through the year. Motivation and side effects collide — and unsupervised patients leave.

With Gila

Coaching where adherence breaks

Gila puts behavior coaching and peer support on the highest-leverage window of the stop curve.

Illustrative stop-rate composite (replace before diligence)Composite
Indian RWE — GI-driven discontinuationNamed

If treatment pauses

Weight regained after stopping · % of prior loss

Without Gila

No plan for stopping

A pause becomes a cliff — published patterns show weight returning hard after cessation.

With Gila

A maintenance track, not a cliff

Gila defines a maintenance path when life interrupts treatment — follow-through, not denial.

Systematic review — post-cessation regainNamed

~12 months

Where the paths land

Without Gila

Where unsupervised paths often land

About 35% stop by a year (~1 in 3; ~2 in 10 by ~6 months). After stopping: ~60% of lost weight back in a year; ~half by week 23 (~5 months) (~5 mo). Relapse happens regardless of who wrote the script — unmanaged outcomes still sit with the pathway.

By week 12 (~3 months)

2/10

By week 26 (~6 months)

2/10

By week 52 (~12 months)

4/10

Regain after stopping

With Gila

Where staying on treatment with Gila aims

Trial averages reach ~20% while people remain on treatment. No invented “Gila vs unsupervised” stop-rate — Gila’s claim is mechanism against named failure points.

Trial averages while staying on treatment

Semaglutide · STEP-1 trial~15% by week 68 (~16 months)
Tirzepatide · SURMOUNT-1 trial~20% by week 72 (~17 months)

Evidence tiers travel with the chips below. Composite stop-rate bands are labeled as such; regain uses the named PMID-41938838 systematic review; Indian RWE (PMID-41798487) is curated alongside the composite.

Illustrative stop-rate composite (replace before diligence)Composite
Indian RWE — GI-driven discontinuationNamed
Systematic review — post-cessation regainNamed
STEP-1 trialNamed
SURMOUNT-1 trialNamed

Clinical intake

Eligibility & clinical intake (India)

India-adjusted BMI (WHO Asia-Pacific / South Asian risk) — not US FDA label cutoffs. Metabolic risk rises at lower BMI in South Asians.

BMI criteria

BMI ≥27 — eligible regardless of comorbidity
BMI ≥25 — eligible with at least one weight-related comorbidity
- Type 2 diabetes or prediabetes
- Hypertension
- Dyslipidemia
- Obstructive sleep apnea
- PCOS
- Fatty liver disease

Waist as supplementary marker: >90 cm men, >80 cm women (South Asian phenotype).

Who assesses

Assessed by an obesity-trained physician, diabetologist, or endocrinologist — not a wellness form.

Contraindications

Personal or family history of MTC or MEN2
Pregnancy or breastfeeding
History of acute or chronic pancreatitis

Baseline bloodwork & intake

HbA1c and/or fasting plasma glucose

Diabetes / prediabetes status

Full lipid profile

Total cholesterol, LDL, HDL, triglycerides

Liver function (ALT, AST)

Baseline and contraindication screen

Renal function (creatinine, eGFR)

Dosing caution in renal impairment

Thyroid function (TSH)

Plus MTC / MEN2 history screen

Pregnancy test

Women of childbearing potential

Consider vitamin B12 and vitamin D

When intake falls under appetite suppression

Waist circumference

Exam measure at intake

Framed from India-adjusted BMI practice (WHO Asia-Pacific / ESI obesity guidance orientation) — not US FDA cutoffs.

What we’re asking you to consider

Starting these medicines without titration, monitoring, adherence, and maintenance often ends in relapse — on the pathway as much as the patient. Gila is built as that system.

If this matches how you want to practise metabolic care, the next step is a partnership conversation — not another unsupervised script.

Book a partnership conversation Evidence desk Patient pitch